What You Will Learn

Please join Carterra and IPA at our upcoming symposium in Cambridge, United Kingdom.

You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Machine Learning and AI Approaches for Protein Engineering
Emerging Targets for Oncology and Beyond
Engineering Bispecific and Multifunctional Antibodies
Characterization for Novel Biotherapeutics

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Companies presenting in 2025:

Agenda	Symposium co-hosted by ImmunoPrecise Antibodies
9:45 – 10:00	Arrive and Check-in
10:00 – 10:30	Networking and Coffee/Tea
10:30 – 10:45	Symposium Begins—Welcome
10:45 – 11:15	Ilse Roodink, PhD, Chief Scientific Officer, ImmunoPrecise Antibodies A multi-parametric humanization approach for single-step engineering to amplify the therapeutic potential of rabbit antibodies
	Abstract: Given the unique biology of antibody maturation in rabbits, this species is an excellent source for identifying diversified panels of target reactive antibodies. However, rabbit antibodies might require more extensive engineering for clinical application compared to traditionally used mouse antibodies. The presented case study highlights strategies to expedite lead selection from a diverse panel of rabbit antibodies. By applying our robust B cell discovery technology combined with high throughout reactivity and epitope landscape profiling, and subsequently utilizing our rapid, scalable in silico-driven humanization platform—which includes thorough risk assessment, early de-risking, and high-throughput in vitro kinetic profiling—a diverse set of optimized antibodies was rapidly delivered for further clinical development.
11:15 – 11:45	Anna Huhn, PhD, Postdoctoral Scientist, University of Oxford Parallel measurements of hundreds of TCR/pMHC affinities to predict TCR crossreactivit
	Abstract: T cells recognise foreign pathogens through peptide antigens presented by the major histocompatibility complex (MHC) via their T-cell receptor (TCR). In cancer therapy, there is a growing focus on engineering T cells with novel TCRs designed to recognise tumour-specific peptide antigens, redirecting immune responses toward cancer cells. However, a significant challenge is the risk of TCR cross-reactivity to self-peptides, which can result in fatal autoimmune toxicity. I will present a protocol to measure hundreds of TCR/pMHC affinities using Carterra’s high-throughput SPR technology. The resulting dataset will enhance our understanding of T cell activation and identify potential TCR cross-reactivity.
11:45 – 12:00	Break
12:00 – 13:00	Lunch and Networking
13:00 – 13:30	Tomas Rodriguez, Industrial Placement, GSK Evaluating Consistent Antibody Affinity Measurements Using Varying Capture Concentrations on Carterra LSA and LSA^XT
	Abstract coming soon
13:30 – 14:00	Abigail Hay, PhD, Postdoctoral Scientist, The Pirbright Institute High-throughput characterisation of the bovine antibody response to foot-and-mouth disease virus
	Abstract: Foot-and-mouth disease virus (FMDV) causes a highly contagious and devastating disease in livestock, posing a continuous threat to food security in Africa, Asia, and the Middle East. The immune response to FMDV is B cell-mediated, with neutralising antibodies playing a crucial role in protection. However, antigenic diversity among viral lineages limits cross-protection. Using non-infectious FMDV virus-like particles on the Carterra LSA^XT, we identified that serial heterologous immunisation generates multiple cross-specific antibodies targeting distinct linear and conformational epitopes. The LSA^XT provides a unique opportunity to study the FMDV epitope landscape at unprecedented resolution and throughput, informing improved vaccination strategies.
14:00 – 14:30	Jon Popplewell, PhD, Field Application Scientist , Carterra *Applications from mAbs to Fragment Screening, How Carterra LSA, LSA^XT and Ultra HT-SPR Platforms Enable Highly Parallel Analysis Advancing All Drug Discovery Modalities*
	Abstract: Carterra’s LSA platforms have set the bar for throughput and scalability for biologics discovery and now extend to small molecule and fragment screening. The Ultra enables a transformative approach to library screening, highly parallel analysis, where many targets can be screened simultaneously against a library. Why run single campaigns when you can screen your entire target backlog simultaneously? This presentation will highlight three interesting application examples: the detailed kinetic characterization of human Fab fragments directly from bacterial extracts, the profiling of binding of TCRs to arrays of immobilized pMHCs, and fragment library screening.
14:30	Symposium Ends

What You Will Learn

Register Here

Agenda